Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 1:14 PM ET

Biotechnology

Company Overview of Regenxbio Inc.

Company Overview

REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company’s development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a p...

1701 Pennsylvania Avenue, NW

Suite 900

Washington, DC 20006

United States

Founded in 2008

18 Employees

Phone:

202-785-7438

Key Executives for Regenxbio Inc.

Chief Executive Officer, President, Director and Member of Disclosure Committee
Age: 40
Chief Financial Officer, Senior Vice President of Corporate Development and Member of Disclosure Committee
Age: 47
Chief Medical Officer and Member of Disclosure Committee
Age: 37
Vice President, General Counsel, Secretary and Member of Disclosure Committee
Age: 39
Chief Scientific Advisor
Age: 60
Compensation as of Fiscal Year 2015.

Regenxbio Inc. Key Developments

REGENX Biosciences Seeks Acquisitions

Regenxbio Inc. is seeking acquisitions. REGENXBIO has filed an IPO in the amount of $100.00 million. The proceeds from the initial public offering will be used for working capital, general and administrative expenses, internal research and development expenses, manufacturing and other general corporate purposes, including in-licenses and potential acquisitions.

REGENXBIO Inc Enters into Strategic Manufacturing Collaboration with WuXi AppTec, Inc

REGENXBIO Inc. announced that it has entered into an exclusive strategic manufacturing collaboration with WuXi AppTec, Inc. Through this collaboration, REGENXBIO plans to establish efficient, scalable manufacturing processes within current Good Manufacturing Practice guidelines for the production of adeno-associated virus gene therapy treatments incorporating REGENXBIO's NAV Technology. Under the terms of the agreement, REGENXBIO and WuXi will establish a proprietary production process for NAV Technology treatments designed to enable the rapid advancement of REGENXBIO's and licensees' therapeutic programs from clinical trials through commercialization in WuXi's 145,000 square-foot cGMP facility currently under construction in Philadelphia. This facility is specially designed to accommodate gene therapy products that contain viral vectors such as REGENXBIO's NAV Technology platform. The partnership will combine REGENXBIO's expertise in AAV process development with WuXi's commercial manufacturing proficiency and established infrastructure. As part of the collaboration, REGENXBIO has already initiated with WuXi the production of material to be used in planned clinical trials. This unique collaboration enables WuXi to work closely with REGENXBIO to provide an integrated solution to its gene therapy needs.

REGENXBIO Inc. Announces Board Changes

REGENXBIO Inc. announced the appointment of Jerry Karabelas, Ph.D., to its board of directors. Most recently, Dr. Karabelas has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences Inc., Vanda Pharmaceuticals Inc. and SkyePharma PLC. He currently chairs the boards of Inotek and Polyphor, AG and is a partner at Care Capital. In addition, the company announced that Daniel Kiser and Michael Gelman have resigned from the board of directors.

Similar Private Companies By Industry

Company Name Region
Evotope Biosciences, Inc. United States
GloboZymes, Inc. United States
Aldagen, Inc. United States
Gulf Nuclear of Louisiana Inc. United States
Synovis Orthopedic and Woundcare, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 15, 2015
--
Private Placement
April 20, 2015
Dimension Therapeutics, Inc.
Private Placement
January 13, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Regenxbio Inc., please visit www.regenxbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.